Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.67 |
| ▸ | RPTOR | Q8N122 | 8/20 | 0.67 |
| ▸ | MLST8 | Q9BVC4 | 8/20 | 0.67 |
| ▸ | GPR6 | P46095 | 5/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133710 | 1.00 | MTOR (0.67) | MTORRPTORMLST8GPR6NSD2 | |
| SCHEMBL22188079 | 0.90 | MTOR (0.73) | MTORRPTORMLST8GPR6PHGDH | |
| SCHEMBL22187975 | 0.88 | MTOR (0.75) | MTORRPTORMLST8GPR6PHGDH | |
| SCHEMBL20133659 | 0.88 | MTOR (0.74) | MTORRPTORMLST8GPR6PHGDH | |
| SCHEMBL20133676 | 0.88 | MTOR (0.74) | MTORRPTORMLST8GPR6PHGDH | |
| SCHEMBL20133657 | 0.86 | MTOR (0.84) | MTORRPTORMLST8GPR6PHGDH | |
| SCHEMBL20129599 | 0.86 | MTOR (0.66) | MTORRPTORMLST8P2RY12DRD2 | |
| SCHEMBL20149875 | 0.82 | MTOR (0.56) | MTORRPTORMLST8P2RY12PHGDH | |
| SCHEMBL22693199 | 0.81 | MTOR (0.64) | MTORRPTORMLST8GPR6P2RY12 | |
| SCHEMBL20133547 | 0.81 | MTOR (0.75) | MTORRPTORMLST8GPR6PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.